within Pharmacolibrary.Drugs.ATC.R;

model R03BA08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0029,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0065,
    k12             = 5.0,
    k21             = 5.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03BA08</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ciclesonide is an inhaled corticosteroid used in the prophylactic treatment of asthma and allergic rhinitis. It is a prodrug that is activated in the lungs to its active metabolite, des-ciclesonide. Ciclesonide is approved and commonly used today for asthma maintenance therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after inhalation administration of ciclesonide.</p><h4>References</h4><ol><li><p>Drollmann, A, et al., &amp; Bethke, TD (2006). Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. <i>Clinical pharmacokinetics</i> 45(7) 729–736. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200645070-00007&quot;>10.2165/00003088-200645070-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16802853/&quot;>https://pubmed.ncbi.nlm.nih.gov/16802853</a></p></li><li><p> (2020). Drugs for COPD. <i>The Medical letter on drugs and therapeutics</i> 62(1606) 137–144. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32960872/&quot;>https://pubmed.ncbi.nlm.nih.gov/32960872</a></p></li><li><p>Nave, R, et al., &amp; Wingertzahn, MA (2009). Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers. <i>Clinical therapeutics</i> 31(12) 2988–2999. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2009.12.002&quot;>10.1016/j.clinthera.2009.12.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20110036/&quot;>https://pubmed.ncbi.nlm.nih.gov/20110036</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03BA08;
